Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1 View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-02-28

AUTHORS

Sunbin Ling, Haiyang Xie, Fan Yang, Qiaonan Shan, Haojiang Dai, Jianyong Zhuo, Xuyong Wei, Penghong Song, Lin Zhou, Xiao Xu, Shusen Zheng

ABSTRACT

BackgroundArsenic trioxide (ATO) is commonly used in the treatment of acute promyelocytic leukemia (APL), but does not benefit patients with solid tumors. When combined with other agents or radiation, ATO showed treatment benefits with manageable toxicity. Previously, we reported that metformin amplified the inhibitory effect of ATO on intrahepatic cholangiocarcinoma (ICC) cells more significantly than other agents. Here, we investigated the chemotherapeutic sensitization effect of metformin in ATO-based treatment in ICC in vitro and in vivo and explored the underlying mechanisms.MethodsICC cell lines (CCLP-1, RBE, and HCCC-9810) were treated with metformin and/or ATO; the anti-proliferation effect was evaluated by cell viability, cell apoptosis, cell cycle, and intracellular-reactive oxygen species (ROS) assays. The in vivo efficacy was determined in nude mice with CCLP-1 xenografts. The active status of AMPK/p38 MAPK and mTORC1 pathways was detected by western blot. In addition, an antibody array was used screening more than 200 molecules clustered in 12 cancer-related pathways in CCLP-1 cells treated with metformin and/or ATO. Methods of genetic modulation and pharmacology were further used to demonstrate the relationship of the molecule. Seventy-three tumor samples from ICC patients were used to detect the expression of ERK3 by immunohistochemistry. The correlation between ERK3 and the clinical information of ICC patients were further analyzed.ResultsMetformin and ATO synergistically inhibited proliferation of ICC cells by promoting cell apoptosis, inducing G0/G1 cell cycle arrest, and increasing intracellular ROS. Combined treatment with metformin and ATO efficiently reduced ICC growth in an ICC xenograft model. Mechanistically, the antibody array revealed that ERK3 exhibited the highest variation in CCLP-1 cells after treatment with metformin and ATO. Results of western blot confirm that metformin and ATO cooperated to inhibit mTORC1, activate AMP-activated protein kinase (AMPK), and upregulate ERK3. Metformin abrogated the activation of p38 MAPK induced by ATO, and this activity was partially dependent on AMPK activation. Inactivation of p38 MAPK by SB203580 or specific short interfering RNA (siRNA) promoted the inactivation of mTORC1 in ICC cells treated with metformin and ATO. Activation of p38 MAPK may be responsible for resistance to ATO in ICC. The relationship between p38 MAPK and ERK3 was not defined by our findings. Finally, AMPK is a newfound positive regulator of ERK3. Overexpression of EKR3 in ICC cells inhibited cell proliferation through inactivation of mTORC1. ERK3 expression is associated with a better prognosis in ICC patients.ConclusionsMetformin sensitizes arsenic trioxide to suppress intrahepatic cholangiocarcinoma via the regulation of AMPK/p38 MAPK-ERK3/mTORC1 pathways. ERK3 is a newfound potential prognostic predictor and a tumor suppressor in ICC. More... »

PAGES

59

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13045-017-0424-0

DOI

http://dx.doi.org/10.1186/s13045-017-0424-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084251884

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28241849


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "AMP-Activated Protein Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arsenic Trioxide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arsenicals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bile Duct Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholangiocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Synergism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heterografts", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mechanistic Target of Rapamycin Complex 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metformin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Nude", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitogen-Activated Protein Kinase 6", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "p38 Mitogen-Activated Protein Kinases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China", 
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ling", 
        "givenName": "Sunbin", 
        "id": "sg:person.01254566214.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254566214.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xie", 
        "givenName": "Haiyang", 
        "id": "sg:person.0657720126.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657720126.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China", 
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "Fan", 
        "id": "sg:person.015745211705.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015745211705.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China", 
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shan", 
        "givenName": "Qiaonan", 
        "id": "sg:person.011471204611.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011471204611.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China", 
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dai", 
        "givenName": "Haojiang", 
        "id": "sg:person.014047645317.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014047645317.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China", 
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhuo", 
        "givenName": "Jianyong", 
        "id": "sg:person.014227113347.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014227113347.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China", 
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wei", 
        "givenName": "Xuyong", 
        "id": "sg:person.0636727021.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636727021.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Song", 
        "givenName": "Penghong", 
        "id": "sg:person.01074572577.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074572577.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhou", 
        "givenName": "Lin", 
        "id": "sg:person.0753155421.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753155421.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China", 
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Xiao", 
        "id": "sg:person.0710354226.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710354226.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.13402.34", 
          "name": [
            "Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China", 
            "Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China", 
            "Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China", 
            "Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zheng", 
        "givenName": "Shusen", 
        "id": "sg:person.0640501242.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640501242.51"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13277-014-2926-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028531309", 
          "https://doi.org/10.1007/s13277-014-2926-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncb2168", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040222650", 
          "https://doi.org/10.1038/ncb2168"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-12-402", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052002226", 
          "https://doi.org/10.1186/1471-2407-12-402"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10147-007-0733-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052754593", 
          "https://doi.org/10.1007/s10147-007-0733-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10238-013-0233-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039015247", 
          "https://doi.org/10.1007/s10238-013-0233-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12029-014-9617-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005572518", 
          "https://doi.org/10.1007/s12029-014-9617-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-02-28", 
    "datePublishedReg": "2017-02-28", 
    "description": "BackgroundArsenic trioxide (ATO) is commonly used in the treatment of acute promyelocytic leukemia (APL), but does not benefit patients with solid tumors. When combined with other agents or radiation, ATO showed treatment benefits with manageable toxicity. Previously, we reported that metformin amplified the inhibitory effect of ATO on intrahepatic cholangiocarcinoma (ICC) cells more significantly than other agents. Here, we investigated the chemotherapeutic sensitization effect of metformin in ATO-based treatment in ICC in vitro and in vivo and explored the underlying mechanisms.MethodsICC cell lines (CCLP-1, RBE, and HCCC-9810) were treated with metformin and/or ATO; the anti-proliferation effect was evaluated by cell viability, cell apoptosis, cell cycle, and intracellular-reactive oxygen species (ROS) assays. The in vivo efficacy was determined in nude mice with CCLP-1 xenografts. The active status of AMPK/p38 MAPK and mTORC1 pathways was detected by western blot. In addition, an antibody array was used screening more than 200 molecules clustered in 12 cancer-related pathways in CCLP-1 cells treated with metformin and/or ATO. Methods of genetic modulation and pharmacology were further used to demonstrate the relationship of the molecule. Seventy-three tumor samples from ICC patients were used to detect the expression of ERK3 by immunohistochemistry. The correlation between ERK3 and the clinical information of ICC patients were further analyzed.ResultsMetformin and ATO synergistically inhibited proliferation of ICC cells by promoting cell apoptosis, inducing G0/G1 cell cycle arrest, and increasing intracellular ROS. Combined treatment with metformin and ATO efficiently reduced ICC growth in an ICC xenograft model. Mechanistically, the antibody array revealed that ERK3 exhibited the highest variation in CCLP-1 cells after treatment with metformin and ATO. Results of western blot confirm that metformin and ATO cooperated to inhibit mTORC1, activate AMP-activated protein kinase (AMPK), and upregulate ERK3. Metformin abrogated the activation of p38 MAPK induced by ATO, and this activity was partially dependent on AMPK activation. Inactivation of p38 MAPK by SB203580 or specific short interfering RNA (siRNA) promoted the inactivation of mTORC1 in ICC cells treated with metformin and ATO. Activation of p38 MAPK may be responsible for resistance to ATO in ICC. The relationship between p38 MAPK and ERK3 was not defined by our findings. Finally, AMPK is a newfound positive regulator of ERK3. Overexpression of EKR3 in ICC cells inhibited cell proliferation through inactivation of mTORC1. ERK3 expression is associated with a better prognosis in ICC patients.ConclusionsMetformin sensitizes arsenic trioxide to suppress intrahepatic cholangiocarcinoma via the regulation of AMPK/p38 MAPK-ERK3/mTORC1 pathways. ERK3 is a newfound potential prognostic predictor and a tumor suppressor in ICC.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13045-017-0424-0", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8373619", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8338918", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1039771", 
        "issn": [
          "1756-8722"
        ], 
        "name": "Journal of Hematology & Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "CCLP-1 cells", 
      "acute promyelocytic leukemia", 
      "ICC patients", 
      "ICC cells", 
      "intrahepatic cholangiocarcinoma", 
      "p38 MAPK", 
      "Western blot", 
      "arsenic trioxide", 
      "antibody array", 
      "cell apoptosis", 
      "G0/G1 cell cycle arrest", 
      "potential prognostic predictor", 
      "intrahepatic cholangiocarcinoma cells", 
      "G1 cell cycle arrest", 
      "anti-proliferation effect", 
      "intracellular reactive oxygen species", 
      "manageable toxicity", 
      "better prognosis", 
      "prognostic predictor", 
      "cell cycle arrest", 
      "treatment benefit", 
      "ICC growth", 
      "promyelocytic leukemia", 
      "clinical information", 
      "xenograft model", 
      "nude mice", 
      "cancer-related pathways", 
      "solid tumors", 
      "metformin", 
      "patients", 
      "vivo efficacy", 
      "AMPK/p38 MAPK", 
      "Combined treatment", 
      "tumor samples", 
      "cholangiocarcinoma cells", 
      "inhibitory effect", 
      "intracellular ROS", 
      "cell proliferation", 
      "cycle arrest", 
      "cholangiocarcinoma", 
      "treatment", 
      "AMPK activation", 
      "cell lines", 
      "genetic modulation", 
      "MAPK", 
      "tumor suppressor", 
      "cell viability", 
      "mTORC1 pathway", 
      "ICC", 
      "activation", 
      "oxygen species", 
      "blot", 
      "cells", 
      "cell cycle", 
      "apoptosis", 
      "proliferation", 
      "active status", 
      "pathway", 
      "sensitization effect", 
      "ConclusionsMetformin", 
      "prognosis", 
      "ResultsMetformin", 
      "protein kinase", 
      "xenografts", 
      "expression", 
      "immunohistochemistry", 
      "leukemia", 
      "tumors", 
      "agents", 
      "inactivation", 
      "mice", 
      "pharmacology", 
      "efficacy", 
      "Mechanistically", 
      "ERK3", 
      "effect", 
      "positive regulator", 
      "arrest", 
      "AMP", 
      "predictors", 
      "vivo", 
      "toxicity", 
      "SB203580", 
      "AMPK", 
      "overexpression", 
      "ATO", 
      "status", 
      "trioxide", 
      "ROS", 
      "suppressor", 
      "mTORC1", 
      "findings", 
      "kinase", 
      "RNA", 
      "modulation", 
      "viability", 
      "activity", 
      "relationship", 
      "role", 
      "benefits", 
      "regulation", 
      "regulator", 
      "correlation", 
      "resistance", 
      "mechanism", 
      "molecules", 
      "samples", 
      "addition", 
      "lines", 
      "results", 
      "growth", 
      "high variation", 
      "cycle", 
      "information", 
      "radiation", 
      "method", 
      "model", 
      "variation", 
      "species", 
      "array"
    ], 
    "name": "Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1", 
    "pagination": "59", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084251884"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13045-017-0424-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28241849"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13045-017-0424-0", 
      "https://app.dimensions.ai/details/publication/pub.1084251884"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_724.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13045-017-0424-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13045-017-0424-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13045-017-0424-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13045-017-0424-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13045-017-0424-0'


 

This table displays all metadata directly associated to this object as RDF triples.

353 TRIPLES      21 PREDICATES      169 URIs      155 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13045-017-0424-0 schema:about N08fb592df03b43aaaea17d88c87af2e9
2 N19ed0d0721d1475282dafd02ba374537
3 N1ad72f2485a54f02b16167ffa07e3db1
4 N282e7168752f402ba517016ec571ccf4
5 N403c29e0dc9844d682e5c85d77ed7d35
6 N4a0bd82650a44bd9ac496809b282e84a
7 N4e9cf1671498427988e79a2848e4a73f
8 N5465ba4aa5794e368265cc7a2d379fec
9 N6271a728a4624697b718d3ce71f41796
10 N7f3731524d5a4fe5a5d3026c6145ed0b
11 N9e7588a1c78a40d6bb3fc1aabb834a09
12 Naeb06bc1fdf747e6bb758cbdeabb8b70
13 Nb310fe6e842143fca5dce98491ef3016
14 Nd4801221e8924e7e80e8461479f6461d
15 Ndc3ef0cd2f434988ad3ed42bacbad521
16 Nf622b66a37ef428b9f04288ddbc2540e
17 Nfbeaef3580f24ee8a8b030e40463f027
18 Nfee2d13193a04b02a9d2afc57c4b0577
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author Ncea24dc59b8c4c59bc8039a7d4741fd8
22 schema:citation sg:pub.10.1007/s10147-007-0733-3
23 sg:pub.10.1007/s10238-013-0233-x
24 sg:pub.10.1007/s12029-014-9617-8
25 sg:pub.10.1007/s13277-014-2926-5
26 sg:pub.10.1038/ncb2168
27 sg:pub.10.1186/1471-2407-12-402
28 schema:datePublished 2017-02-28
29 schema:datePublishedReg 2017-02-28
30 schema:description BackgroundArsenic trioxide (ATO) is commonly used in the treatment of acute promyelocytic leukemia (APL), but does not benefit patients with solid tumors. When combined with other agents or radiation, ATO showed treatment benefits with manageable toxicity. Previously, we reported that metformin amplified the inhibitory effect of ATO on intrahepatic cholangiocarcinoma (ICC) cells more significantly than other agents. Here, we investigated the chemotherapeutic sensitization effect of metformin in ATO-based treatment in ICC in vitro and in vivo and explored the underlying mechanisms.MethodsICC cell lines (CCLP-1, RBE, and HCCC-9810) were treated with metformin and/or ATO; the anti-proliferation effect was evaluated by cell viability, cell apoptosis, cell cycle, and intracellular-reactive oxygen species (ROS) assays. The in vivo efficacy was determined in nude mice with CCLP-1 xenografts. The active status of AMPK/p38 MAPK and mTORC1 pathways was detected by western blot. In addition, an antibody array was used screening more than 200 molecules clustered in 12 cancer-related pathways in CCLP-1 cells treated with metformin and/or ATO. Methods of genetic modulation and pharmacology were further used to demonstrate the relationship of the molecule. Seventy-three tumor samples from ICC patients were used to detect the expression of ERK3 by immunohistochemistry. The correlation between ERK3 and the clinical information of ICC patients were further analyzed.ResultsMetformin and ATO synergistically inhibited proliferation of ICC cells by promoting cell apoptosis, inducing G0/G1 cell cycle arrest, and increasing intracellular ROS. Combined treatment with metformin and ATO efficiently reduced ICC growth in an ICC xenograft model. Mechanistically, the antibody array revealed that ERK3 exhibited the highest variation in CCLP-1 cells after treatment with metformin and ATO. Results of western blot confirm that metformin and ATO cooperated to inhibit mTORC1, activate AMP-activated protein kinase (AMPK), and upregulate ERK3. Metformin abrogated the activation of p38 MAPK induced by ATO, and this activity was partially dependent on AMPK activation. Inactivation of p38 MAPK by SB203580 or specific short interfering RNA (siRNA) promoted the inactivation of mTORC1 in ICC cells treated with metformin and ATO. Activation of p38 MAPK may be responsible for resistance to ATO in ICC. The relationship between p38 MAPK and ERK3 was not defined by our findings. Finally, AMPK is a newfound positive regulator of ERK3. Overexpression of EKR3 in ICC cells inhibited cell proliferation through inactivation of mTORC1. ERK3 expression is associated with a better prognosis in ICC patients.ConclusionsMetformin sensitizes arsenic trioxide to suppress intrahepatic cholangiocarcinoma via the regulation of AMPK/p38 MAPK-ERK3/mTORC1 pathways. ERK3 is a newfound potential prognostic predictor and a tumor suppressor in ICC.
31 schema:genre article
32 schema:isAccessibleForFree true
33 schema:isPartOf N3b9cadc531e14c9283cf8eb9a359f4f2
34 N5ded33dc46ae42db88525087966ee1db
35 sg:journal.1039771
36 schema:keywords AMP
37 AMPK
38 AMPK activation
39 AMPK/p38 MAPK
40 ATO
41 CCLP-1 cells
42 Combined treatment
43 ConclusionsMetformin
44 ERK3
45 G0/G1 cell cycle arrest
46 G1 cell cycle arrest
47 ICC
48 ICC cells
49 ICC growth
50 ICC patients
51 MAPK
52 Mechanistically
53 RNA
54 ROS
55 ResultsMetformin
56 SB203580
57 Western blot
58 activation
59 active status
60 activity
61 acute promyelocytic leukemia
62 addition
63 agents
64 anti-proliferation effect
65 antibody array
66 apoptosis
67 array
68 arrest
69 arsenic trioxide
70 benefits
71 better prognosis
72 blot
73 cancer-related pathways
74 cell apoptosis
75 cell cycle
76 cell cycle arrest
77 cell lines
78 cell proliferation
79 cell viability
80 cells
81 cholangiocarcinoma
82 cholangiocarcinoma cells
83 clinical information
84 correlation
85 cycle
86 cycle arrest
87 effect
88 efficacy
89 expression
90 findings
91 genetic modulation
92 growth
93 high variation
94 immunohistochemistry
95 inactivation
96 information
97 inhibitory effect
98 intracellular ROS
99 intracellular reactive oxygen species
100 intrahepatic cholangiocarcinoma
101 intrahepatic cholangiocarcinoma cells
102 kinase
103 leukemia
104 lines
105 mTORC1
106 mTORC1 pathway
107 manageable toxicity
108 mechanism
109 metformin
110 method
111 mice
112 model
113 modulation
114 molecules
115 nude mice
116 overexpression
117 oxygen species
118 p38 MAPK
119 pathway
120 patients
121 pharmacology
122 positive regulator
123 potential prognostic predictor
124 predictors
125 prognosis
126 prognostic predictor
127 proliferation
128 promyelocytic leukemia
129 protein kinase
130 radiation
131 regulation
132 regulator
133 relationship
134 resistance
135 results
136 role
137 samples
138 sensitization effect
139 solid tumors
140 species
141 status
142 suppressor
143 toxicity
144 treatment
145 treatment benefit
146 trioxide
147 tumor samples
148 tumor suppressor
149 tumors
150 variation
151 viability
152 vivo
153 vivo efficacy
154 xenograft model
155 xenografts
156 schema:name Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1
157 schema:pagination 59
158 schema:productId N2526d6973eb8422782f0ce63798249b8
159 N2630b47570684bda99e793ac772d76e3
160 Nac48e87a6b834a8ea1aaee73766b0c83
161 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084251884
162 https://doi.org/10.1186/s13045-017-0424-0
163 schema:sdDatePublished 2022-09-02T16:00
164 schema:sdLicense https://scigraph.springernature.com/explorer/license/
165 schema:sdPublisher Nd4e55c6c35484c4787b9378af1243609
166 schema:url https://doi.org/10.1186/s13045-017-0424-0
167 sgo:license sg:explorer/license/
168 sgo:sdDataset articles
169 rdf:type schema:ScholarlyArticle
170 N08fb592df03b43aaaea17d88c87af2e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name p38 Mitogen-Activated Protein Kinases
172 rdf:type schema:DefinedTerm
173 N0ae441e3fffa418091a22c45deabf9e2 rdf:first sg:person.01074572577.12
174 rdf:rest N99d6028919ea47918a02265ae35f5441
175 N148b9e7baa684968aaee7949521e5d49 rdf:first sg:person.0657720126.04
176 rdf:rest N3f309ee3345d4fc7b9d848506888d853
177 N1606bf84179841b79e95ee0eedf7ec4a rdf:first sg:person.0640501242.51
178 rdf:rest rdf:nil
179 N19ed0d0721d1475282dafd02ba374537 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Animals
181 rdf:type schema:DefinedTerm
182 N1ad72f2485a54f02b16167ffa07e3db1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Metformin
184 rdf:type schema:DefinedTerm
185 N2526d6973eb8422782f0ce63798249b8 schema:name pubmed_id
186 schema:value 28241849
187 rdf:type schema:PropertyValue
188 N2630b47570684bda99e793ac772d76e3 schema:name doi
189 schema:value 10.1186/s13045-017-0424-0
190 rdf:type schema:PropertyValue
191 N282e7168752f402ba517016ec571ccf4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Arsenic Trioxide
193 rdf:type schema:DefinedTerm
194 N3b9cadc531e14c9283cf8eb9a359f4f2 schema:issueNumber 1
195 rdf:type schema:PublicationIssue
196 N3f309ee3345d4fc7b9d848506888d853 rdf:first sg:person.015745211705.07
197 rdf:rest N98005162c20e43edba55bbcf5e0d69ef
198 N403c29e0dc9844d682e5c85d77ed7d35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Heterografts
200 rdf:type schema:DefinedTerm
201 N4a0bd82650a44bd9ac496809b282e84a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Mitogen-Activated Protein Kinase 6
203 rdf:type schema:DefinedTerm
204 N4e9cf1671498427988e79a2848e4a73f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Arsenicals
206 rdf:type schema:DefinedTerm
207 N5465ba4aa5794e368265cc7a2d379fec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Humans
209 rdf:type schema:DefinedTerm
210 N5ded33dc46ae42db88525087966ee1db schema:volumeNumber 10
211 rdf:type schema:PublicationVolume
212 N6271a728a4624697b718d3ce71f41796 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Signal Transduction
214 rdf:type schema:DefinedTerm
215 N68f10855e8c144f08f4b1377dc8e5b72 rdf:first sg:person.0710354226.21
216 rdf:rest N1606bf84179841b79e95ee0eedf7ec4a
217 N79a758813d73478fa6334f9686ead9cb rdf:first sg:person.014047645317.35
218 rdf:rest Nacaf056ec99e4eda8fd2406c216fd755
219 N7f3731524d5a4fe5a5d3026c6145ed0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Bile Duct Neoplasms
221 rdf:type schema:DefinedTerm
222 N98005162c20e43edba55bbcf5e0d69ef rdf:first sg:person.011471204611.80
223 rdf:rest N79a758813d73478fa6334f9686ead9cb
224 N99d6028919ea47918a02265ae35f5441 rdf:first sg:person.0753155421.39
225 rdf:rest N68f10855e8c144f08f4b1377dc8e5b72
226 N9e7588a1c78a40d6bb3fc1aabb834a09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
227 schema:name Mechanistic Target of Rapamycin Complex 1
228 rdf:type schema:DefinedTerm
229 Nac48e87a6b834a8ea1aaee73766b0c83 schema:name dimensions_id
230 schema:value pub.1084251884
231 rdf:type schema:PropertyValue
232 Nacaf056ec99e4eda8fd2406c216fd755 rdf:first sg:person.014227113347.05
233 rdf:rest Nb391d73406404f2481e3e4aa48d89ccb
234 Naeb06bc1fdf747e6bb758cbdeabb8b70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Oxides
236 rdf:type schema:DefinedTerm
237 Nb310fe6e842143fca5dce98491ef3016 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
238 schema:name Cholangiocarcinoma
239 rdf:type schema:DefinedTerm
240 Nb391d73406404f2481e3e4aa48d89ccb rdf:first sg:person.0636727021.03
241 rdf:rest N0ae441e3fffa418091a22c45deabf9e2
242 Ncea24dc59b8c4c59bc8039a7d4741fd8 rdf:first sg:person.01254566214.57
243 rdf:rest N148b9e7baa684968aaee7949521e5d49
244 Nd4801221e8924e7e80e8461479f6461d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
245 schema:name Mice, Nude
246 rdf:type schema:DefinedTerm
247 Nd4e55c6c35484c4787b9378af1243609 schema:name Springer Nature - SN SciGraph project
248 rdf:type schema:Organization
249 Ndc3ef0cd2f434988ad3ed42bacbad521 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
250 schema:name Cell Line, Tumor
251 rdf:type schema:DefinedTerm
252 Nf622b66a37ef428b9f04288ddbc2540e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
253 schema:name Mice
254 rdf:type schema:DefinedTerm
255 Nfbeaef3580f24ee8a8b030e40463f027 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
256 schema:name Drug Synergism
257 rdf:type schema:DefinedTerm
258 Nfee2d13193a04b02a9d2afc57c4b0577 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
259 schema:name AMP-Activated Protein Kinases
260 rdf:type schema:DefinedTerm
261 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
262 schema:name Medical and Health Sciences
263 rdf:type schema:DefinedTerm
264 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
265 schema:name Oncology and Carcinogenesis
266 rdf:type schema:DefinedTerm
267 sg:grant.8338918 http://pending.schema.org/fundedItem sg:pub.10.1186/s13045-017-0424-0
268 rdf:type schema:MonetaryGrant
269 sg:grant.8373619 http://pending.schema.org/fundedItem sg:pub.10.1186/s13045-017-0424-0
270 rdf:type schema:MonetaryGrant
271 sg:journal.1039771 schema:issn 1756-8722
272 schema:name Journal of Hematology & Oncology
273 schema:publisher Springer Nature
274 rdf:type schema:Periodical
275 sg:person.01074572577.12 schema:affiliation grid-institutes:grid.13402.34
276 schema:familyName Song
277 schema:givenName Penghong
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074572577.12
279 rdf:type schema:Person
280 sg:person.011471204611.80 schema:affiliation grid-institutes:grid.13402.34
281 schema:familyName Shan
282 schema:givenName Qiaonan
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011471204611.80
284 rdf:type schema:Person
285 sg:person.01254566214.57 schema:affiliation grid-institutes:grid.13402.34
286 schema:familyName Ling
287 schema:givenName Sunbin
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254566214.57
289 rdf:type schema:Person
290 sg:person.014047645317.35 schema:affiliation grid-institutes:grid.13402.34
291 schema:familyName Dai
292 schema:givenName Haojiang
293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014047645317.35
294 rdf:type schema:Person
295 sg:person.014227113347.05 schema:affiliation grid-institutes:grid.13402.34
296 schema:familyName Zhuo
297 schema:givenName Jianyong
298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014227113347.05
299 rdf:type schema:Person
300 sg:person.015745211705.07 schema:affiliation grid-institutes:grid.13402.34
301 schema:familyName Yang
302 schema:givenName Fan
303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015745211705.07
304 rdf:type schema:Person
305 sg:person.0636727021.03 schema:affiliation grid-institutes:grid.13402.34
306 schema:familyName Wei
307 schema:givenName Xuyong
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636727021.03
309 rdf:type schema:Person
310 sg:person.0640501242.51 schema:affiliation grid-institutes:grid.13402.34
311 schema:familyName Zheng
312 schema:givenName Shusen
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640501242.51
314 rdf:type schema:Person
315 sg:person.0657720126.04 schema:affiliation grid-institutes:grid.13402.34
316 schema:familyName Xie
317 schema:givenName Haiyang
318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657720126.04
319 rdf:type schema:Person
320 sg:person.0710354226.21 schema:affiliation grid-institutes:grid.13402.34
321 schema:familyName Xu
322 schema:givenName Xiao
323 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710354226.21
324 rdf:type schema:Person
325 sg:person.0753155421.39 schema:affiliation grid-institutes:grid.13402.34
326 schema:familyName Zhou
327 schema:givenName Lin
328 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753155421.39
329 rdf:type schema:Person
330 sg:pub.10.1007/s10147-007-0733-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052754593
331 https://doi.org/10.1007/s10147-007-0733-3
332 rdf:type schema:CreativeWork
333 sg:pub.10.1007/s10238-013-0233-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1039015247
334 https://doi.org/10.1007/s10238-013-0233-x
335 rdf:type schema:CreativeWork
336 sg:pub.10.1007/s12029-014-9617-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005572518
337 https://doi.org/10.1007/s12029-014-9617-8
338 rdf:type schema:CreativeWork
339 sg:pub.10.1007/s13277-014-2926-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028531309
340 https://doi.org/10.1007/s13277-014-2926-5
341 rdf:type schema:CreativeWork
342 sg:pub.10.1038/ncb2168 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040222650
343 https://doi.org/10.1038/ncb2168
344 rdf:type schema:CreativeWork
345 sg:pub.10.1186/1471-2407-12-402 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052002226
346 https://doi.org/10.1186/1471-2407-12-402
347 rdf:type schema:CreativeWork
348 grid-institutes:grid.13402.34 schema:alternateName Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
349 schema:name Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China
350 Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
351 Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou, China
352 Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang Province, China
353 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...